anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For ARDS patients with moderate to severe mechanical ventilation(MAQUET), give 6-8ml/kg (ideal body weight PBW), and control the plateau pressure to \<30cmH2O; In patients with respiratory distress, the tidal volume can be increased to 7-8ml/kg (PBW), while the plateau pressure is \<30cmH2O. Adjust breathing rate according to CO2 level, up to 35 breaths/min. PBW, male: 50+0.91 (height cm-152.4); female: 45.5+0.91 (height cm-152.4).
FIELD: medicine. SUBSTANCE: method deals with treating diseases associated with different genetic disorders obtained during patient's life or caused as a result of inherited pathology. The method deals with applying either lactoferrin (LF) and/or its conjugates as a carrier of foreign genetic information for gene therapy. At injecting laboratory animals with complexes of intact LF and plasmid DNA, containing different marker genes, genetic material penetrates tissues possessing membranous LF receptors and is expressed there. Moreover, synthesis of end products of introduced genes' expression is observed in different groups of muscular fibers. Expression of marker genes in different tissues takes place, also, at injecting complexes of DNA along with LF derivatives containing either DNA-condensing polycation or DNA-condensing polycation and high-molecular polymeric carrier - dextran or phycol. Efficiency of complex-formation with LF or with its derivatives and subsequent delivery of genetic material into cells depends upon plasmid nature. Advantage of the present innovation is in the fact that the mentioned product could be used in the field of gene therapy of different human and animal diseases. EFFECT: higher efficiency. 2 cl, 3 dwg
The basis of Ketogenic Therapy is an altered macronutrient intake. It is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate and carbohydrate is minimal. On Ketogenic Therapy, the body metabolizes fat, producing ketones as an energy source for the brain. Induction of ketosis has been shown to correlate with the reduction of seizures observed with Ketogenic Therapy. A major challenge of Ketogenic Therapy in children is that the compounds provided to stop seizure activity are the same compounds provided for growth and development. The altered macronutrient ratio that is the basis of Ketogenic Therapy is also a potential risk factor for dyslipidemia and may adversely affect growth. The investigators will evaluate efficacy of Ketogenic Therapy by assessing seizures and requirements for antiepileptic drugs. The investigators will evaluate adverse effects of Ketogenic Therapy by assessing dyslipidemia and growth. The investigators will foster optimal daily administration of therapy with structured training programs for caregivers.
Objectives: Illicit drug use affects tens of millions of Americans and costs nearly $200 billion annually in health care costs and lost productivity. Cocaine dependence accounts for 25% of reported lifetime drug dependence though few successfully abstain with treatment. For efforts toward positive long-term outcomes, it is imperative to identify risk factors of poor outcomes, specialized treatments, neural mechanisms that change with treatment, and predictive measures of treatment outcomes. Substance abusers are known to have dysregulation in cue reactivity, reward processing, executive control, and intrinsic network connectivity. Non-invasive brain stimulation (NIBS) has proven effective at reducing drug craving in nicotine, alcohol, and cocaine users. Here, intermittent theta-burst stimulation (iTBS), a type of NIBS, delivered to left dorsolateral prefrontal cortex (dlPFC) is implemented to modulate substance abuse related circuit dysregulations and assess the relationship of iTBS-induced changes in circuitry to ongoing cocaine use.
PURPOSE: To enable to supply a useful drug into a body without limitation in the usage by the subject preparation with a means to protect the drug while staying in the preparation, a means to transfer the useful drug from the preparation to the outside, and a communication means between the outside and the inner chamber of the preparation. CONSTITUTION: A main body 11 of the preparation for medication 10 comprises a wall part 12 surrounding an inner chamber. The preparation for medication 10 has at least one path 13 to supply useful drug components from the preparation 10 into a living body. The preparation for medication 10 has a dome-shaped end 8 to simplify medication of preparation into a host animal, and its front end 9 is also formed dome-shaped. At least one part of the wall part 12 is made of semipermeable wall forming components. A first component contains a useful drug 15 and a bio-compatible carrier 16, and a second component contains an expansible driving agents 17. An inner chamber 14 has a protecting means 19 to protect the useful drug 15 which is sensitive to the fluid existing in the environment where the drug is applied in a living body.
Colorectal cancer is a second commonest tumor in Hong Kong and the second commonest cause of cancer related death. About 1 in 23 males will develop colorectal cancer in his life time. The disease tends to cluster in families. This may be a combination of factors including shared genes, shared environment or chance. Known familial syndromes occur in only about 5% of cases. The majority is not well understood and labelled sporadic colorectal cancer. The screening strategy in families of subjects with colorectal cancer has not been defined. Colonoscopy is among the most sensitive and specific screening tool for colorectal neoplasm. The current study determines the prevalence of adenomas among first degree relatives of patients diagnosed with colorectal cancer. To quantify risk in this cohort, a case control analysis is used. The prevalence of the cohort is compared to that of a control population. The control group consists of relatives of patients with normal colonoscopic findings during the same study period.
Medulloblastoma (MB), a prevalent pediatric central nervous system tumor, is influenced by microRNAs (miRNAs) that impact tumor initiation and progression. However, the specific involvement of miRNAs in MB tumorigenesis remains unclear. Using single-cell RNA sequencing, we identified ROR2 expression in normal human fetal cerebellum. Subsequent analyses, including immunofluorescence, quantitative real-time PCR (qRT-PCR), and Western blot, assessed ROR2 expression in MB tissues and cell lines. We investigated miR-124-3p and miR-194-5p and their regulatory role in ROR2 expression through the dual-luciferase reporter, qRT-PCR, and western blot assays. Mechanistic insights were gained through functional assays exploring the impact of miR-124-3p, miR-194-5p, and ROR2 on MB growth in vitro and in vivo. We observed significantly reduced miR-124-3p and miR-194-5p expression and elevated ROR2 expression in MB tissues and cell lines. High ROR2 expression inversely correlated with overall survival in WNT and SHH subgroups of MB patients. Functionally, overexpressing miR-124-3p and miR-194-5p and inhibiting ROR2 suppressed in vitro malignant transformation and in vivo tumorigenicity. Mechanistically, miR-124-3p and miR-194-5p synergistically regulated the ROR2/PI3K/Akt pathway, influencing MB progression. Our findings indicate that miR-124-3p and miR-194-5p function as tumor suppressors, inhibiting MB progression via the ROR2/PI3K/Akt axis, suggesting a key mechanism and therapeutic targets for MB patients.
M1 macrophages induce protective immunity against infection, but also contribute to metabolic and inflammatory diseases. Here we show that the E3 ubiquitin ligase, MDM2, promotes the glycolytic and inflammatory activities of M1 macrophage by increasing the production of IL-1β, MCP-1 and nitric oxide (NO). Mechanistically, MDM2 triggers the ubiquitination and degradation of E3 ligase, SPSB2, to stabilize iNOS and increases production of NO, which s-nitrosylates and activates HIF-1α for triggering the glycolytic and pro-inflammatory programs in M1 macrophages. Myeloid-specific haplodeletion of MDM2 in mice not only blunts LPS-induced endotoxemia and NO production, but also alleviates obesity-induced adipose tissue-resident macrophage inflammation. By contrast, MDM2 haplodeletion induces higher mortality, tissue damage and bacterial burden, and also suppresses M1 macrophage response, in the cecal ligation and puncture-induced sepsis mouse model. Our findings thus identify MDM2 as an activator of glycolytic and inflammatory responses in M1 macrophages by connecting the iNOS-NO and HIF-1α pathways.
The present invention provides a new class of non-viral transduction vectors that can be used for both in vivo and in vitro applications. In particular, these vectors can be used for gene transfer applications. These new gene transduction vectors can achieve transfer efficiencies far greater to commercially available polymeric and liposomal gene transfer vectors while maintaining little or no toxicity in vitro. Their low in vitro toxicity makes them ideal candidates for in vivo use. The present invention also provides a gene transfer vector that has comparable efficiency to a viral vector without the potential for a life-threatening immune response. Furthermore, the unique polycationic structure of these polymers associates with many suitable biologically active molecule, including oligonucleotides and polypeptides and other compounds that poses multiple cationic sites. The polymer can act as a delivery vehicle for the associated biologically active molecule, in vivo or in vitro, to the cells of interest for the biologically active molecule. Complexes according to the invention or portions thereof, can comprise a cellular delivery molecule or agent that can facilitate the translocation of the complex or portion thereof into cells. In some embodiments, cellular delivery molecules for use in the present invention may comprise one or more one or more polymers of the present invention, e.g., polyamides, dendritic macromolecules (polymers comprising an oligoamine shell and a cyclodextrin core), and carbohydrate-containing degradable polyesters.
Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
PURPOSE: An oral formulation containing dry granules of limaprost or limaprost alfadex is provided to ensure stability during processes and after packing and to improve productivity. CONSTITUTION: A dry granule contains limaprost or limaprost alpha-cyclodextrin encapsulated compound; or microshellac and shellactose. The dry granule additionally contains pharmaceutically acceptable additives. A pharmaceutical composition with improved stability contains the dry granule and pharmaceutically acceptable additive. A formulation for oral administration with improved stability contains the composition. The formulation is a tablet, powder, granule, or capsule. A method for manufacturing the formulation for oral administration comprises: a step of mixing limaprost or limaprost alfadex with microshellac or shellactose; a step of pressing the mixture and drying and granulating; and a step of mixing the dry granules with pharmaceutically acceptable additives. [Reference numerals] (AA) Moisture absorption test(25°C/75%RH); (BB) Moisture absorption; (CC) Elapse time; (DD) Embodiment 1; (EE) Comparative embodiment 4; (FF) Commercial formulation
The control group will receive instructions on applying warm compresses, the current standard of care. The patient or parent/guardian will be directed to apply a warm compress to the abscess or soak the area in warm water for 15 minutes. The application/soak will be done 4 times during the day.
Women with intellectual and developmental disabilities (I/DD) are less likely to receive cervical cancer screening (CCS) relative to women without disabilities. Primary care providers (PCPs) play key roles in recommending CCS. The purpose of this study was to identify factors PCPs consider when recommending and performing CCS for women with I/DD. Using a qualitative approach, in-depth semi-structured interviews (N = 13) were conducted with majority family medicine-trained PCPs. Through inductive data analysis, it was found that most PCPs reported recommending CCS; however, follow-through for performing CCS varied. PCPs attempted to align their CCS recommendations with national guidelines and provided counseling and education to families and patients about CCS while taking an individualized risk-benefit approach. Despite most PCPs reporting a lack of knowledge or training related to providing I/DD-specific care, PCPs attempted to draw upon experiences with similar populations to recommend and perform CCS. There is an opportunity to improve knowledge of PCPs related to performing CCS for women with I/DD.
BACKGROUND: Somatic complaints are persistently reported in patients with coronary heart disease (CHD). Sex and gender influence health and well-being in a variety of ways, but it is unknown how they affect somatic complaints over time after percutaneous coronary intervention (PCI). Therefore, we examined the association between sex and gender on somatic health complaints during the first month (acute) and the first two years (recovery) after PCI.
METHODS: 514 patients (Mage = 64.2 ± 8.9, 84.2% male) completed the somatic scale of the Health Complaints Scale (including the subscales: cardiopulmonary complaints, fatigue, sleep problems) at baseline, one, 12-, and 24-months post-PCI. In a follow-up study, they filled in additional questionnaires to gauge gender norms, traits, and identity. Linear mixed modeling analyses were used to assess the influence of sex, gender, their interaction, and covariates on somatic complaints for the acute and recovery phases separately.
RESULTS: A general decline in somatic complaints over time was observed during the acute phase, followed by a stabilization in the recovery phase. Females and individuals with more feminine traits, norms, and identities reported increased somatic complaints. Males with more pronounced feminine norms and females with more masculine norms likewise reported more somatic, cardiopulmonary, and fatigue complaints. Furthermore, age, cardiac history, and comorbid diseases partly explained the associations with somatic complaints.
CONCLUSION: While somatic complaints improve post-PCI, there are still conspicuous sex and gender differences that need to be considered. Future research should further elaborate upon these discrepancies and incorporate sex and gender in prevention and develop tailored interventions to diminish somatic complaints.
Patients being started on azathioprine should be informed of the necessity of periodic blood counts while they are receiving the drug and should be encouraged to report any unusual bleeding or bruising to their physician. They should be informed of the danger of infection while receiving azathioprine and asked to report signs and symptoms of infection to their physician. Careful dosage instructions should be given to the patient, especially when azathioprine is being administered in the presence of impaired renal function or concomitantly with allopurinol (see Drug Interactionssubsection and DOSAGE AND ADMINISTRATION). Patients should be advised of the potential risks of the use of azathioprine during pregnancy and during the nursing period. The increased risk of malignancy following therapy with azathioprine should be explained to the patient. 

Repackaged By / Distributed By: RemedyRepack Inc.

625 Kolter Drive, Indiana, PA 15701

(724) 465-8762
The study will consist of 2 parts (Part-I and Part-II). In Part I of the study, kidney transplant recipients who are low-risk for rejection and meet the inclusion and exclusion criteria for study Part-I will be approached for informed consent in the peri-transplant period, defined as 7 days before to 5 days after transplantation. Basic clinical history and kidney transplant function that are reviewed for routine transplant care are utilized to screen patients who are approached for study discussion and informed consent.

Patients who agree to participation in the study will have received Thymoglobulin induction of at least 4.5 mg/Kg body weight total dose. These patients will have their corticosteroids withdrawn by day 30 post-transplantation and will be followed with kidney function labs at least weekly through day-90 post-transplantation. Withdrawal of corticosteroids in patients who are immunologically at low risk for acute rejection similar to this study population and have received at least 4.5 mg/kg total dose of Thymoglobulin is standard practice. Patients meeting inclusion and exclusion criteria for Part-II of the study will continue with the study. Those failing to meet the inclusion/exclusion criteria for Part-II of the study will conclude the study and will be followed per CPMC standard of care.

In Part II, study patients will be randomized to one of the two groups in a 2:1 ratio. Two patients will be randomized to the study group for every one patient to the standard of care group. A total of 75 patients will be enrolled. Fifty to the study group and 25 to the standard of care group. The patients will have post transplantation follow-up labs as standard of care and clinic visits also as standard of care. There are no additional clinic visits for the study purposes or study procedures. TruGraf blood will be collected at the same time as the standard of care blood tests and additional phlebotomy is not required.
OBJECTIVE: This study aimed to assess the clinical efficacy of combining multi-slice spiral CT with gastrointestinal angiography for diagnosing gastric cancer.
METHODS: We conducted a retrospective analysis of clinical data from 151 patients with suspected gastric cancer admitted to our hospital between January 2014 and January 2022. Among them, 70 patients underwent multi-slice spiral CT alone (control group), while the remaining 81 patients underwent multi-slice spiral CT in combination with gastrointestinal barium contrast (combination group). Finally, pathological examination confirmed gastric cancer in 81 patients. We analyzed the diagnostic efficacy of multi-slice spiral CT combined with gastrointestinal angiography for staging gastric cancer and detecting lymph node metastasis.
RESULTS: The sensitivity and accuracy of diagnosing gastric cancer using multi-slice spiral CT combined with gastrointestinal angiography were significantly superior to CT alone (P < .05). This combined approach exhibited substantial advancements in detecting stage I and II tumors compared to a single CT, although the difference in stage III detection rate was marginal (P < .05). Furthermore, among the 81 gastric cancer cases, 67 were confirmed to have lymph node metastasis through surgical and pathological examination. The lymph node detection rate with multi-slice spiral CT combined with gastrointestinal angiography was significantly higher than that achieved with single CT (P < .05).
CONCLUSIONS: Combining multi-slice spiral CT with gastrointestinal angiography proved to be an effective diagnostic strategy for gastric cancer.
Hydrophobic liquids are encapsulated by dispersing them as droplets in a liquid which either reacts with a substance added to the hydrophobic liquid or contains a substance which reacts with the hydrophobic liquid or with a substance added to it, so as to form a polymeric shell enclosing each droplet.  A table (not shown) defining the substances and their reactive pairs is given, at least one of the two substances consisting of or comprising two or more same or different kinds of functional groups selected from the isocyanate, amino, imino, isothiocyanate, acid chloride, hydroxyl, methylol and chloroformate groups.  As an example of forming capsules which when attached to a sheet, form a carbon paper when used with another supporting medium carrying electronically inductive inorganic clays, the following is given.  Leucomalachite green and "Desmodur L" (T.M. for an addition compound of toluylene diisocyanate and hexanetriol) are dissolved in dichlorodiphenyl to form a first liquid.  Caustic soda and "Monogen S" (T.M. for a sodium sulphonate of a higher alcohol) are dissolved in water to form a second liquid into which the first is dispersed as droplets.  The droplets are encapsulated by the reaction product.
The present invention relates to an applicator for providing an active composition to a surface, the applicator comprising: cellulosic substrates having anionic sites (e.g., paper, laminated paperboard, cardboard, or woven or non-woven plant fabric such as wood pulp or cotton material); and impregnated or coated compositions comprising a bioactive cationic component in an amount sufficient to deactivate anionic sites in the cellulosic substrate and provide desired effects such as biocidal effects, enhanced skin feel, enhanced skin health, and fabric softening. The applicator may take the form of a wipe having a single or multiple layers of cellulosic substrate. The applicator is preferably substantially dry. The invention also relates to an applicator for providing an active composition to a surface, the applicator comprising at least two layers of cellulosic substrates having anionic sites; the layers are adhered to one another by an adhesive composition comprising a cationic component in an amount sufficient to deactivate anionic sites in the cellulosic substrate and provide the desired effect. The adhesive composition may further comprise a water-soluble or water-dispersible adhesive polymer. The invention also relates to methods of making and using the applicators, for example, to disinfect skin or inanimate surfaces.
Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
The invention relates to new pharmaceutical compositions comprising bismuth in the form of water-soluble proteinaceous complexes which are reversibly precipitable by alcohol, nondialysable and in which the bismuth is strongly bound. Preparations comprising the complexes are therapeutically useful for treating and prophylaxis against ulcers and inflammations, in particular of the gastro-intestinal tract. Altered soluble globular proteins, particularly enzymes are a preferred ligand. The preferred complexes are formed by the reaction of soluble proteinaceous material with a soluble source of bismuth in aqueous solution at up to 60 DEG  C. and pH 9-10. The formation of the complexes may be tested for by alcohol precipitation and/or gel filtration. These methods may also be used to concentrate the complexes.